Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amélie Petitprez"'
Autor:
Alexandre E. Escargueil, Amélie Petitprez, Virginie Poindessous, Annette K. Larsen, Gérard Bastian, Eric Guérin, Djamila Ouaret, Marie Regairaz
Publikováno v:
International Journal of Oncology. 42:1644-1653
Irinotecan is a major anticancer agent specifically targeting DNA topoisomerase I. Its cytotoxicity is mediated via a two-step process involving accumulation of reversible DNA‑topoisomerase I complexes associated with transient DNA single-strand br
Autor:
Annette K. Larsen, Amélie Petitprez
Publikováno v:
Current Pharmaceutical Design. 19:958-964
Irinotecan is a major drug for treatment of metastatic colorectal cancer and a promising agent for other applications like gastric cancer. Its clinical activity is currently limited by both intrinsic (natural) and acquired drug resistance. A better u
Autor:
Christophe Tournigand, Virginie F. Mégalophonos, Pascale Cervera, Aude Battistella, Benoist Chibaudel, Sylvie Dumont, Pascaline Boudou, Thierry André, Jean-François Fléjou, Aimery de Gramont, Nyam Kamsu-Kom, Virginie Poindessous, Annette K. Larsen, Djamila Ouaret, Alexandre E. Escargueil, Amélie Petitprez, Karima El Ouadrani
Publikováno v:
Clinical Cancer Research. 17:6522-6530
Purpose: Epidermal growth factor receptor (EGFR) and VEGF(R) signaling show extensive cross-talk, providing a rationale for joint targeting of the two pathways. However, combinations of monoclonal antibodies (mAb) targeting EGFR and VEGF showed disap
Autor:
Olivier Poch, Pierre Oudet, Armin Maier, Erwan Pencreach, Marie-Pierre Gaub, Annette K. Larsen, Anne Schneider, Dino Moras, Agnès Neuville, Amélie Petitprez, Serge Rohr, Dominique Guenot, Wolfgang Raffelsberger, Philippe Bachellier, Eric Guérin
Publikováno v:
Molecular medicine (Cambridge, Mass.). 18
Topoisomerase I is a privileged target for widely used anticancer agents such as irinotecan. Although these drugs are classically considered to be DNA-damaging agents, increasing evidence suggests that they might also influence the tumor environment.
Publikováno v:
Pharmacologytherapeutics. 131(1)
The last decade has witnessed the approval of monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs) for targeting of oncogenic signaling pathways. Generally, the clinical activity of these agents has been less than expecte
Autor:
Djamila Ouaret, Virginie F. Mégalophonos, Annette K. Larsen, A. de Gramont, Alexandre E. Escargueil, Virginie Poindessous, Aude Batistella, K. El Ouadrani, Christophe Tournigand, Amélie Petitprez
Publikováno v:
Journal of Clinical Oncology. 29:443-443
443 Background: The extensive cross-talk between EGFR and VEGF(R) argues for joint targeting of the two signaling pathways. Unexpectedly, large clinical trials with combinations of EGFR-targeted antibodies and bevacizumab, a VEGF-blocking antibody, s
Autor:
Pascale Cervera, Christophe Louvet, Djamila Ouaret, Karima El Ouadrani, Pascaline Boudou, Alexandre E. Escargueil, Jean-François Fléjou, Virginie Poindessous, Christophe Tournigand, Nyam Kamsu‐Kom, Annette K. Larsen, Amélie Petitprez, Aimery de Gramont, Sylvie Dumont
Publikováno v:
Molecular Cancer Therapeutics. 8:A240-A240
Backgound: Combining different classes of targeted agents represents a major challenge in modern cancer therapy. Agents targeting EGFR- or VEGF-signaling are approved for treatment of metastatic colorectal cancer paving the way for novel therapeutic